NCT00925132View on ClinicalTrials.gov

Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

November 30, 2014

Study Completion Date

December 31, 2016

Conditions
Metastatic Melanoma
Interventions
DRUG

Temozolomide, Decitabine, Panobinostat

"Temozolomide - given each cycle.~Decitabine - 6 cohorts with dose escalation.~Panobinostat - 6 cohorts with dose escalation."

Trial Locations (1)

52242

University of Iowa Hospitals and Clinics, Iowa City

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Holden Comprehensive Cancer Center

OTHER

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of Iowa

OTHER